Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY10 | O00398 | 10/20 | 0.54 |
| ▸ | GPR34 | Q9UPC5 | 7/20 | 0.54 |
| ▸ | GPR174 | Q9BXC1 | 6/20 | 0.54 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.50 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.50 |
| ▸ | FABP3 | P05413 | 1/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22762 | 0.99 | P2RY10 (0.55) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| SCHEMBL27566251 | 0.99 | P2RY10 (0.55) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| SCHEMBL28180536 | 0.99 | P2RY10 (0.55) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| Hydrochloric Acid SCHEMBL28242944 | 0.98 | P2RY10 (0.54) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| SCHEMBL28263018 | 0.98 | P2RY10 (0.54) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| SCHEMBL14092739 | 0.91 | P2RY10 (0.53) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| Dimethylaminoethanol SCHEMBL28331606 | 0.90 | P2RY10 (0.47) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| Choline SCHEMBL28243279 | 0.90 | FABP3 (0.54) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| SCHEMBL14092747 | 0.86 | P2RY10 (0.51) | P2RY10GPR34GPR174 | |
| SCHEMBL417532 | 0.86 | P2RY10 (0.73) | P2RY10GPR34GPR174LPAR3LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108676800-A | The inhibition led using the mediated rnai of hepatitis type B virus (HBV) gene expression of short interfering nucleic acid (siNA) | 瑟纳治疗公司 | 2018-10-19 | — | — | CN | disclosed |
| CN-103282497-B | RNA interference-mediated suppression of Hepatitis B Virus (HBV) gene expression using short interfering nucleic acids (siNA) | 瑟纳治疗公司 | 2018-07-10 | — | — | CN | disclosed |
| CN-107090456-A | The connection albumen led using the mediated rnai of short interfering nucleic acid（Cadherin related protein matter）, the suppression of the gene expressions of β 1 | 瑟纳治疗公司 | 2017-08-25 | — | — | CN | disclosed |
| CN-103068980-B | RNA interference mediated inhibition of the catenin (cadherin-associated protein), beta 1 (CTNNB 1) gene expression using short interfering nucleic acids (siNA) | 瑟纳治疗公司 | 2017-04-05 | — | — | CN | disclosed |